source
- TRex Bio targets $111M IPO as Retension and Lycia also prepare public listingsTRex Bio, backed by Eli Lilly, filed with the SEC to raise about $111.3 million by offering 8.3 million shares priced between $14 and $16. If the midpoint price is achieved, the company expects net…
- UK regulator to shift from one-off checks to continuous monitoring of AI medical devicesThe UK’s Medicines and Healthcare products Regulatory Agency announced a new policy that will require continuous monitoring of AI‑driven medical devices, replacing the current one‑time review model…